Morepen files first US drug application, eyes generic diabetes market
The Hindu Business Line - Sep 28, 2026
Morepen’s first US submission targets a late-stage entry into the global diabetes therapeutics market, leveraging a DPP-4 inhibitor with potential competitive timelines and regulatory milestones